OBJECTIVES:
Rotavirus is the one of important disease for Turkey. It was reported that 500.000 child admitted to hospitals due Rotavirus in Turkey per year. Total cost of Rotavirus to Turkish economy was reported as US$ 40 million per year. The aim of study is reflects the government perspective attributed to investing in Rotavirus Vaccination(RV) in Turkey, and how changes in morbidity and mortality influence government expenditure over many generations. METHODS: The model applies a generational accounting approach for estimating the inter-temporal fiscal impact of policy changes with accounting for direct fiscal transfers between age cohorts and the State during different life stages while simultaneously accounting for rotavirus medical costs, and how rotavirus mortality and morbidity influence government fiscal transfers. Costs are expressed in US $(1 US$ ϭ 1.75 TL). The model is constructed using Turkish life tables, rotavirus related and unrelated health care costs, employment earnings adjusted for age and social parameters. The model compares vaccinated and unvaccinated cohorts against rotavirus using discounted net tax revenues for different vaccine cost like US$ 36,24 and 12. RESULTS: Discounted Net Tax Revenue(DNTR) between vaccinated and unvaccinated cohorts for vaccine cost US$ 12 was US$ 84 and US $ 98 million for 25 and 50 years, respectively. DNTR for vaccine cost US$ 24 and US$ 36 were US$ 19 and US$ 33 million, US$ (-) 45 and US$ (-) 32 million, respectively. Investing in rotavirus vaccination represented return for government at year 25 and 50 for vaccine cost US$ 12 and US$ 24. Vaccine cost US$ 36 didn't represent return for government. CONCLUSIONS: Long-term government net tax revenues were sensitive to vaccine prices, therefore it is an important determinant of economic value of the vaccine. Investments in RV prevention could also deliver early cost-offsets related to the reduced health care expenditure in Turkey. OBJECTIVES: By means of «Budget impact analysis» define what type of surgical gowns and drapes: disposable or reusable, is more rational to apply in surgery. METHODS: Budget impact analysis was provided. The study estimated direct costs: expenses for reusable and disposable gowns and drapes usage, drug therapy and late complications (peritonitis, sepsis, phlegmon and abscess) treatment. Effectiveness data was taken from 2 clinical trials: «Moylan J.A., Fitzpatrick K.T., Davenport K.E. Reducing wound infections. Improved gown and drape barrier perfomance. Arch Surg. -1987» and «Surgical site infection by surgical category and type of incision -5 years from July 2004 to June 2009, England». Risk of postoperative complications development was the main effectiveness criterion. Two types of surgical linen were compared: simple surgical sheet, as an example of reusable surgical linen, and a set of disposable gowns ad drapes. RESULTS: It was established that the use of disposable surgical linen provides more effectiveness in comparison with reusable analogs. Calculation of total expenses for use of 2 compared alternatives showed that use of disposable surgical linen is economically more favorable (285,4 $ for 1 operation carrying out) in comparison with the application of reusable surgical analogs (603,6 $). Transition to this alternative scheme of medical care allows to buy additional number of surgical sets (1 673 sets during one year), on the money saved as a result of this transition. Unifactor sensivity analysis was carried out, which showed that results of our pharmacoeconomic study were stable. CONCLUSIONS: Total costs of disposable surgical linen usage (428 100 $ for 1 500 operation carrying out during 1 year) appeared to be much less, than those of reusable analogs application (905 400 $). That is why disposable gowns and drapes can be recommended as economic. 
PIH8 COMPARATIVE PHARMACOECONOMIC STUDY OF DISPOSABLE AND REUSABLE GOWNS AND DRAPES

PIH9 COMPARE HEALTH CARE UTILIZATION AND COSTS AMONG MENOPAUSAL WOMEN WITH DIFFERENT SYMPTOMS BY LINKING WOMEN'S REGISTRY AND CLAIMS DATABASE
OBJECTIVES:
Apply probabilistic linkage to add menopause symptoms recorded in a registry database to claims data, and compare health care utilizations and costs among women with and without symptoms. METHODS: Menopausal women age Ն45 prescribed estrogen only hormone therapy from a large U.S. claims database (04/01/2005-09/30/2008) were linked with the University of Michigan Women's Registry Database menopausal group using probabilistic linkage, controlling for osteoporosis, gynecological disorders/procedures, genital infection, bladder/pelvic floor support problem, gynecology system cancer, breast condition, gut condition, hormone disorder, nerve problem, and other comorbidities (rheumatoid disease, depression, blood clotting). After linkage, registry patients' menopause symptoms were added to claims database records. The same linkage procedures were repeated 250 times, the mean and 95% confidence interval (CI) of health care costs and utilizations during the follow-up period were compared between women with and without symptoms. RESULTS: Among 80 matched patients, 84% had at least one symptom, with hot flashes being the most common. The average cost of patients with at least one symptom was much higher than of patients without symptoms ($13, 570 [95% CI: $13, 680] , p-valueϽ0.001). Women with symptoms were more likely to have inpatient (12.78% vs. 4.05%, PϽ0.001), outpatient emergency room (20.6% vs. 6.31%, pϽ0.001), and physician visits (79.86% vs. 18.71%, pϽ0.001). CONCLUSIONS: Women with menopause symptoms incur higher health care utilizations and costs than those without. Results suggest that symptoms can be an important predictor of economic outcomes. Therefore, it would be beneficial to control for them using probabilistic linkage to bridge the gap between registry and claims data.
PIH10 COST EFFECTIVENESS COMPARISON BETWEEN DIENOGEST AND GONADOTROPIN-RELEASING HORMONE ANALOGS IN TURKEY
Marmarali B 1 , Deger C 1 , Memis SA 1 , Parali E 1 , Sumer F 1 , Karakeben K 1 , Kayadibinli M 2 1 Bayer Türk, Istanbul, Turkey, 2 STATinMED Research, Istanbul, Turkey OBJECTIVES: To evaluates and compares the cost effectiveness of 2mg dienogest versus gonadotropin-releasing hormone analogs (GnRH-a) for endometriosis treatment. Some treatments only eliminate endometriosis symptoms while others shrink and reduce lesions in addition to symptom treatment. In this context, dienogest was compared to the class of GnRH analogs, which are used in Turkey for both symptomatic treatment and as a contributor to shrinkage/reduction of the endometriotic lesions. METHODS: The population consisted of women age 18 to 49 eligible for GnRH-a treatment. GnRH-a treatment included leuprolide acetate (3 months intramuscular / subcutaneous injection 11.25mg, 1 syringe/box) and goserelin acetate implant (3.6 mg 1 syringe/box). A Markov model was used to simulate three health outcomes: treatment response, unresponsive to treatment and death. Costs were assessed and compared between the 2mg dienogest group versus the selected GnRH-a group over a 2-year time period. Clinical endpoints were quality adjusted life years (QALY) and mean response time (Ն50% improvement in Visual Analog Scale[VAS] pain score) in health status when a patient responded to treatment. Model output was calculated as incremental cost per QALY and per respondent years gained. RESULTS: A 2-year model was utilized for GnRH-a therapy and supporting treatment, and a 1-year model for treatment without supportive therapy. Study results showed that dienogest had the same efficiency but lower health care costs according to incremental cost per QALY and per respondent years gained for both the 1 and 2-year models. Sensitivity analysis for treatment response and regression rate also showed that 2mg dienogest was a more cost-effective treatment option than GnRH-a agents. CONCLUSIONS: Results demonstrate that 2mg dienogest is a more cost-effective option to treat endometriosis compared with both GnRH-a agents. This result may assist with reimbursement plan selection for endometriosis treatment from payers' perspectives.
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